Archives
-
3X (DYKDDDDK) Peptide Workflow Guide
2026-10-01
Build more sensitive FLAG-tagged protein workflows for purification, detection, and structural biology with a small, hydrophilic tandem epitope. This guide connects practical 3X FLAG peptide handling with substrate-driven translocon research, including membrane-protein complex isolation and metal-sensitive assay design.
-
PTX3–TLR4/NF-κB–FGF21 Axis in Steroid ONFH
2026-09-30
Li and colleagues identify pentraxin 3 (PTX3) as a protective regulator of glucocorticoid-induced osteonecrosis of the femoral head and position it upstream of a TLR4/NF-κB/FGF21 signaling axis. By combining patient samples, cellular perturbation, knockout mice, recombinant PTX3 rescue, and pathway blockade, the study offers a mechanistic framework for impaired osteogenesis and apoptosis in steroid-associated ONFH.
-
Phosphatase Inhibitor Cocktail K1015 Guide
2026-09-30
The Phosphatase Inhibitor Cocktail K1015 is a dual-component system for protein phosphorylation preservation during lysate preparation. Its sequentially added Tube A and Tube B components address serine/threonine, tyrosine, acid, and alkaline phosphatase activity in research workflows.
-
Patient-Derived Gastric Cancer Assembloids Explained
2026-09-29
The reference study develops gastric cancer assembloids by combining patient-matched tumor organoids with tumor-derived stromal subpopulations. Its findings show that stromal composition reshapes gene expression and drug sensitivity, supporting more physiologically relevant studies of tumor–stroma interactions and personalized treatment responses.
-
Angiotensin II, Ferroptosis, and NPC Radioresistance
2026-09-29
The reference study identifies a local angiotensin II–AGT–HIF-1α–HILPDA pathway that suppresses ferroptosis and promotes radioresistance in nasopharyngeal carcinoma. Its combination of mechanistic signaling analysis, ferroptosis measurements, radiosensitivity assays, and xenograft validation supports joint evaluation of angiotensin II blockade and ferroptosis induction, while also highlighting candidate biomarkers for treatment response.
-
EZ Cap™ Cas9 mRNA: Spatial CRISPR Design
2026-09-28
EZ Cap™ Cas9 mRNA (m1Ψ) supports controlled CRISPR-Cas9 genome editing in mammalian cells. This article presents a region-aware strategy for connecting Cas9 editing with transcriptomic analysis, using CD52-deficient male reproductive tissues as a model for better assay design.
-
Clozapine Workflows for Schizophrenia Research
2026-09-28
Use Clozapine to connect receptor pharmacology, prefrontal ERK1/2 readouts, and liver-safety controls in schizophrenia research. This workflow also shows how to use it as a carefully bounded pharmacological comparator—not a substitute for targeted magnetic stimulation studies of GABRE.
-
Syringin and Sunitinib in Renal Cell Carcinoma
2026-09-27
A 2024 study reports that Syringin suppresses renal cell carcinoma cell growth and migration, promotes apoptosis, and increases in vitro sensitivity to sunitinib. By combining network pharmacology, molecular docking, cell-based assays, and pathway analysis, the researchers implicate EGFR/PI3K/Akt signaling while leaving clinical efficacy and the mechanism of drug sensitization to be tested.
-
Quercetin Beyond the Pathway: Translational Strategy
2026-09-26
Quercetin offers translational researchers a useful way to interrogate kinase signaling, cell-death mechanisms, and inflammatory biology—provided its broad pharmacology is matched with careful controls. This article connects cancer-research mechanisms with preclinical neuroinflammation findings and outlines practical steps for designing interpretable experiments without overstating clinical relevance.
-
KPT330 Tunes Cas9 Precision Through mRNA Export
2026-09-25
The study identifies selective inhibitors of nuclear export, including KPT330, as indirect modulators of Cas9 activity: they interfere with Cas9 mRNA export rather than directly inhibiting the nuclease. In human cells, this approach improved the reported specificity of genome and base editing, while also inhibiting prime editing, and highlights mRNA trafficking as a potential control point for CRISPR systems.
-
VX-661: A Practical F508del CFTR Corrector Workflow
2026-09-25
Build a trafficking-first assay around VX-661, then separate rescued surface expression from channel function to see where the response is gained or lost. A benchmark treatment and calnexin-aware experimental design help make F508del CFTR results more interpretable across models.
-
EZ Cap™ Cas9 mRNA (m1Ψ) for Zygote Editing
2026-09-24
Pair capped, modified Cas9 mRNA with a guide RNA to build a transient CRISPR-Cas9 genome-editing workflow, including electroporation-based delivery to mouse zygotes. The article separates published electroporation benchmarks from product-handling guidance and highlights the controls needed to optimize editing without overlooking embryo viability.
-
Autophagy–Metastasis Signature in Colorectal Cancer
2026-09-24
Bai et al. developed a six-gene prognostic signature connecting autophagy and liver-metastasis-associated expression patterns with colorectal cancer outcomes, then examined its relationship to immune-cell states and treatment-response predictions. The integrated bulk and single-cell analyses suggest an immunosuppressive, potentially immunotherapy-resistant high-risk phenotype, while leaving clinical validation and causal testing as important next steps.
-
PPARα Suppresses Pyroptosis in LCA Liver Injury
2026-09-23
A 2026 study reports that PPARα activation attenuates lithocholic acid-induced cholestatic liver injury while suppressing two pyroptosis-associated pathways: NLRP3 signaling and APAF1/CASPASE-3/GSDME signaling. The findings connect nuclear-receptor activity with inflammatory cell-death mechanisms and provide a rationale for testing PPARα agonism in cholestatic liver models, while leaving clinical relevance and pathway causality to be established.
-
Septin4, VHL, and HIF-1α in Hypoxic Cardiomyocytes
2026-09-23
The reference study identifies Septin4 as a previously unrecognized aggravator of hypoxia-induced cardiomyocyte injury. Its data support a mechanism in which Septin4 binds HIF-1α and promotes VHL-dependent ubiquitination and proteasomal degradation, weakening an adaptive response to oxygen deprivation.